EGFR testing in lung cancer is ready for prime time

The Lancet Oncology

Volumn 10, Issue 5, 2009, Pages 432-433

  Hirsch, Fred R ^a   Bunn Jr , Paul A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER CONTROL; CLINICAL TRIAL; DRUG SENSITIVITY; ETHNICITY; EXON; GENE AMPLIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; METASTASIS; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

CARCINOMA, NON-SMALL-CELL LUNG; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 65349161510     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70110-X     Document Type: Letter

References (12)

1. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
2. Sequist L.V., Martins R.G., Spigel D., et al. First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26 (2008) 2442-2449
3. Mok T.S., Leong S., Liu X., et al. Gefitinib vs carboplatin/paclitaxel in clinically selected chemonaive patients with advanced non-small cell lung cancer in Asia (IPASS): Randomized, open-label, phase III study. J Thorac Oncol 3 (2008) 1487 (abst).
4. Hirsch F.R., Dziadziuszko R., Camidge D.R., et al. Biomarker status correlates with clinical benefit: Phase 2 study of single-agent erlotinib (E) or E intercalated with carboplatin and paclitaxel in an EGFR biomarker selected population. J Thorac Oncol 3 (2008) S267
5. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21 (2003) 3798-3807
6. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 5034-5042
7. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
8. Hirsch F.R., Herbst R.S., Olsen C., et al. Increased EGFR gene copy number detected by FISH predicts ourcome in non-small cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 26 (2008) 3351-3357
9. Pirker R., Szczesna A., von Pawel J., et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer. J Clin Oncol 26 (2008) S1006
10. Lynch T.J., Patel T., Dreisbach L., et al. A randomized mulitcenter phase III study of cetuximab (Erbitux) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC). J Thorac Oncol 2 (2007) S340
11. Maheswaran S., Sequist L.V., Nagrath S., et al. Detection of mutations in EGFR in circulating lung cancer cells. N Engl J Med 359 (2008) 366-377
12. Richardson F., Richardson K., Sennello G., et al. Biomarker analysis of tumor tissue from completed resected NSCLC patients enrolled in an adjuvant trial (RADIANT). J Thorac Oncol 3 (2008) S269